Testing T-DXd or chemo for HER2-low or HR-positive breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This study looks at treatment choices for adults with breast cancer that has spread and cannot be removed by surgery (unresectable metastatic disease). It focuses on people with HER2-low (and some HER2-ultralow) and/or hormone-receptor positive cancer, and compares how well treatments like T-DXd or standard chemotherapy work.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older and have breast cancer that has spread and cannot be removed with surgery
- Have biopsy or test results confirming either HER2-low (IHC 1+ or IHC 2+ with ISH negative) and/or HR-positive cancer, depending on your group
- You are starting a new treatment now (either T-DXd or standard chemotherapy) based on your doctor’s plan
- If you are in the hormone-receptor (HR+) group: you must have had at least one hormone (endocrine) treatment for metastatic cancer
- If you are in the HR+ group: you must NOT have had chemotherapy for metastatic cancer before
- You cannot be pregnant or breastfeeding, and you must not currently be in a blinded drug study that could affect results
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well the drug T-DXd (Enhertu) works against breast cancer that has spread or can't be removed with surgery. It includes patients with any level of HER2 protein, so it might be an option even if your cancer has low HER2.
This trial tests a targeted drug combination for HER2-positive, hormone-receptor-positive breast cancer that has spread. It aims to shrink tumors and control the disease for as long as possible, with a planned switch to maintenance therapy after initial response.
This trial compares two treatments for advanced breast cancer that is HR-positive, HER2-low or ultralow, and a non-luminal subtype. It tests if a targeted antibody-drug conjugate (T-DXd) works better than the usual first-line therapy combining a CDK4/6 inhibitor with hormone therapy. This study is for people who have not had any treatment for advanced disease.
This study tests a drug called T-DXd (trastuzumab deruxtecan) for people with advanced breast cancer that has very low levels of HER2 (a protein that helps cancer grow) and that is also hormone receptor positive. The goal is to see if this drug can help shrink or slow the cancer.
This trial tests a targeted antibody-drug medicine (trastuzumab deruxtecan, T-DXd) in people with metastatic breast cancer that is HER2-low or HER2 IHC 0. It may help by treating tumors that haven’t previously received anti-HER2 treatment in the metastatic setting.
This study follows women with advanced breast cancer (metastatic) who have hormone-receptor positive tumors and low HER2 levels, to see how well a new drug called Trastuzumab Deruxtecan works when used in routine clinical care after prior hormone therapy.
Hear when a new Unresectable Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.